Effects of sustained-release tulobuterol on asthma control and β-adrenoceptor function

Hiroaki Kume, Masashi Kondo, Yasushi Ito, Ryujiro Suzuki, Kenichi Yamaki, Kenzo Takagi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

1. Recently, a patch formulation of tulobuterol, a β-adrenoceptor (AR) agonist, has been developed using a transdermal delivery system. The present study was designed to determine whether β-AR function and asthma control were affected by the sustained-released β-AR agonist. 2. Tulobuterol (2 mg) was applied daily for 8 weeks to seven patients with bronchial asthma in whom the morning dip in the peak expiratory flow (PEF) rate developed even though inhaled glucocorticoids were being taken. After treatment with tulobuterol, the early morning reduction in PEF was suppressed and PEF values were increased from 367 ± 35 to 439 ± 38 L/min (P < 0.05). The rescue use of inhaled β-AR agonists was decreased from 6.9 ± 2.0 to 1.0 ± 0.7 puffs/week (P < 0.01). Symptom scores also decreased from 8.3 ± 3.4 to 2.1 ± 1.4 score/week (P < 0.01). 3. Next, we sought to examine the effects of exposure to tulobuterol on β-AR function in guinea-pig tracheal smooth muscle. After exposure of tissues to tulobuterol (0.01-10 μmol/L) for 45 min, the inhibitory effects of tulobuterol on methacholine-induced contractions were attenuated in a concentration-dependent manner. However, the inhibitory effects of tulobuterol were not affected after exposure to 0.01 μmol/L tulobuterol (a concentration greater than serum levels in clinical use). In contrast, the inhibitory effects of procaterol were not affected after exposure to tulobuterol under the same experimental conditions. 4. These results indicate that the combination of sustained-released tulobuterol with inhaled glucocorticoid therapy is beneficial to patients with bronchial asthma who suffer from symptoms induced by the morning dip in PEF. Moreover, chronic exposure to lower concentrations of tulobuterol does not lead to desensitization of β-AR in airway smooth muscle.

Original languageEnglish
Pages (from-to)1076-1083
Number of pages8
JournalClinical and Experimental Pharmacology and Physiology
Volume29
Issue number12
DOIs
Publication statusPublished - 12-11-2002

Fingerprint

Adrenergic Receptors
Asthma
Glucocorticoids
Smooth Muscle
tulobuterol
Procaterol
Peak Expiratory Flow Rate
Methacholine Chloride
Guinea Pigs
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pharmacology
  • Physiology (medical)

Cite this

Kume, Hiroaki ; Kondo, Masashi ; Ito, Yasushi ; Suzuki, Ryujiro ; Yamaki, Kenichi ; Takagi, Kenzo. / Effects of sustained-release tulobuterol on asthma control and β-adrenoceptor function. In: Clinical and Experimental Pharmacology and Physiology. 2002 ; Vol. 29, No. 12. pp. 1076-1083.
@article{3727807e77254204a218714b2361b066,
title = "Effects of sustained-release tulobuterol on asthma control and β-adrenoceptor function",
abstract = "1. Recently, a patch formulation of tulobuterol, a β-adrenoceptor (AR) agonist, has been developed using a transdermal delivery system. The present study was designed to determine whether β-AR function and asthma control were affected by the sustained-released β-AR agonist. 2. Tulobuterol (2 mg) was applied daily for 8 weeks to seven patients with bronchial asthma in whom the morning dip in the peak expiratory flow (PEF) rate developed even though inhaled glucocorticoids were being taken. After treatment with tulobuterol, the early morning reduction in PEF was suppressed and PEF values were increased from 367 ± 35 to 439 ± 38 L/min (P < 0.05). The rescue use of inhaled β-AR agonists was decreased from 6.9 ± 2.0 to 1.0 ± 0.7 puffs/week (P < 0.01). Symptom scores also decreased from 8.3 ± 3.4 to 2.1 ± 1.4 score/week (P < 0.01). 3. Next, we sought to examine the effects of exposure to tulobuterol on β-AR function in guinea-pig tracheal smooth muscle. After exposure of tissues to tulobuterol (0.01-10 μmol/L) for 45 min, the inhibitory effects of tulobuterol on methacholine-induced contractions were attenuated in a concentration-dependent manner. However, the inhibitory effects of tulobuterol were not affected after exposure to 0.01 μmol/L tulobuterol (a concentration greater than serum levels in clinical use). In contrast, the inhibitory effects of procaterol were not affected after exposure to tulobuterol under the same experimental conditions. 4. These results indicate that the combination of sustained-released tulobuterol with inhaled glucocorticoid therapy is beneficial to patients with bronchial asthma who suffer from symptoms induced by the morning dip in PEF. Moreover, chronic exposure to lower concentrations of tulobuterol does not lead to desensitization of β-AR in airway smooth muscle.",
author = "Hiroaki Kume and Masashi Kondo and Yasushi Ito and Ryujiro Suzuki and Kenichi Yamaki and Kenzo Takagi",
year = "2002",
month = "11",
day = "12",
doi = "10.1046/j.1440-1681.2002.03777.x",
language = "English",
volume = "29",
pages = "1076--1083",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "12",

}

Effects of sustained-release tulobuterol on asthma control and β-adrenoceptor function. / Kume, Hiroaki; Kondo, Masashi; Ito, Yasushi; Suzuki, Ryujiro; Yamaki, Kenichi; Takagi, Kenzo.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 29, No. 12, 12.11.2002, p. 1076-1083.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of sustained-release tulobuterol on asthma control and β-adrenoceptor function

AU - Kume, Hiroaki

AU - Kondo, Masashi

AU - Ito, Yasushi

AU - Suzuki, Ryujiro

AU - Yamaki, Kenichi

AU - Takagi, Kenzo

PY - 2002/11/12

Y1 - 2002/11/12

N2 - 1. Recently, a patch formulation of tulobuterol, a β-adrenoceptor (AR) agonist, has been developed using a transdermal delivery system. The present study was designed to determine whether β-AR function and asthma control were affected by the sustained-released β-AR agonist. 2. Tulobuterol (2 mg) was applied daily for 8 weeks to seven patients with bronchial asthma in whom the morning dip in the peak expiratory flow (PEF) rate developed even though inhaled glucocorticoids were being taken. After treatment with tulobuterol, the early morning reduction in PEF was suppressed and PEF values were increased from 367 ± 35 to 439 ± 38 L/min (P < 0.05). The rescue use of inhaled β-AR agonists was decreased from 6.9 ± 2.0 to 1.0 ± 0.7 puffs/week (P < 0.01). Symptom scores also decreased from 8.3 ± 3.4 to 2.1 ± 1.4 score/week (P < 0.01). 3. Next, we sought to examine the effects of exposure to tulobuterol on β-AR function in guinea-pig tracheal smooth muscle. After exposure of tissues to tulobuterol (0.01-10 μmol/L) for 45 min, the inhibitory effects of tulobuterol on methacholine-induced contractions were attenuated in a concentration-dependent manner. However, the inhibitory effects of tulobuterol were not affected after exposure to 0.01 μmol/L tulobuterol (a concentration greater than serum levels in clinical use). In contrast, the inhibitory effects of procaterol were not affected after exposure to tulobuterol under the same experimental conditions. 4. These results indicate that the combination of sustained-released tulobuterol with inhaled glucocorticoid therapy is beneficial to patients with bronchial asthma who suffer from symptoms induced by the morning dip in PEF. Moreover, chronic exposure to lower concentrations of tulobuterol does not lead to desensitization of β-AR in airway smooth muscle.

AB - 1. Recently, a patch formulation of tulobuterol, a β-adrenoceptor (AR) agonist, has been developed using a transdermal delivery system. The present study was designed to determine whether β-AR function and asthma control were affected by the sustained-released β-AR agonist. 2. Tulobuterol (2 mg) was applied daily for 8 weeks to seven patients with bronchial asthma in whom the morning dip in the peak expiratory flow (PEF) rate developed even though inhaled glucocorticoids were being taken. After treatment with tulobuterol, the early morning reduction in PEF was suppressed and PEF values were increased from 367 ± 35 to 439 ± 38 L/min (P < 0.05). The rescue use of inhaled β-AR agonists was decreased from 6.9 ± 2.0 to 1.0 ± 0.7 puffs/week (P < 0.01). Symptom scores also decreased from 8.3 ± 3.4 to 2.1 ± 1.4 score/week (P < 0.01). 3. Next, we sought to examine the effects of exposure to tulobuterol on β-AR function in guinea-pig tracheal smooth muscle. After exposure of tissues to tulobuterol (0.01-10 μmol/L) for 45 min, the inhibitory effects of tulobuterol on methacholine-induced contractions were attenuated in a concentration-dependent manner. However, the inhibitory effects of tulobuterol were not affected after exposure to 0.01 μmol/L tulobuterol (a concentration greater than serum levels in clinical use). In contrast, the inhibitory effects of procaterol were not affected after exposure to tulobuterol under the same experimental conditions. 4. These results indicate that the combination of sustained-released tulobuterol with inhaled glucocorticoid therapy is beneficial to patients with bronchial asthma who suffer from symptoms induced by the morning dip in PEF. Moreover, chronic exposure to lower concentrations of tulobuterol does not lead to desensitization of β-AR in airway smooth muscle.

UR - http://www.scopus.com/inward/record.url?scp=0036032972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036032972&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1681.2002.03777.x

DO - 10.1046/j.1440-1681.2002.03777.x

M3 - Article

C2 - 12390295

AN - SCOPUS:0036032972

VL - 29

SP - 1076

EP - 1083

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 12

ER -